We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The two treatment arms in the study were standard of care alone, including antiviral treatments and corticosteroids, and standard of care plus a single dose of otilimab. Read More
AstraZeneca’s and Amgen’s biologic drug tezepelumab reduced the rate of asthma attacks by 56 percent among patients with severe and uncontrolled forms of the condition, according to their just-released phase 3 trial results. Read More
A single dose of the Pfizer/BioNTech vaccine significantly lowers asymtopmatic SARS-CoV-2 infections, which means it also reduces the risk of transmission from asymtopmatic individuals, a new UK study has shown. Read More
The company also temporarily stopped all sales of its approved gene therapy Zynteglo, a treatment for the blood disorder beta thalassemia that uses the same the same lentiviral vector. Read More
A new UK study has found that statins did not have any overall effect on muscle symptoms in patients who had previously reported them when taking the medications, suggesting that statins may not responsible for the muscle pains associated with taking them. Read More
The Pfizer/BioNTech COVID-19 vaccine showed the same effectiveness for all age groups — including individuals over age 60 — confirmed a new study from Israel that included almost 1.2 million individuals. Read More
Pfizer and BioNTech have begun assessing the safety and immunogenicity of a third dose of their COVID-19 vaccine against the coronavirus’ South African mutation and other potential viral variants. Read More
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) will soon begin a phase 1 clinical trial of Moderna’s variant-specific COVID-19 vaccine candidate, mRNA-1273.351, which has been tailored to better protect against the virus’ South African mutation. Moderna will also conduct trials of its own. Read More
Fujifilm is betting that Avigan, which inhibits the RNA polymerase enabling the flu virus to replicate, will work against the coronavirus, another RNA virus. Read More
In December, GSK and Sanofi suffered a setback during their phase 1/2 trial, when their vaccine was found to produce only a weak immune response in older patients. Read More
RSS
